Greinwald J H, Burke D K, Sato Y, Poust R I, Kimura K, Bauman N M, Smith R J
Division of Pediatric Otolaryngology, Department of Otolaryngology, University of Iowa, Iowa City, 52242, USA.
Otolaryngol Head Neck Surg. 1999 Oct;121(4):381-7. doi: 10.1016/S0194-5998(99)70225-1.
Picibanil (OK-432) is a sclerosing agent derived from a low-virulence strain of Streptococcus pyogenes that induces regression of macrocystic lymphangiomas. This report describes a prospective, nonrandomized trial to evaluate the efficacy of Picibanil in the treatment of 13 affected children ranging in age from 1 to 94 months. On average, 4.1 fluoroscopically guided intracystic injections were performed per child, with an average total dose of 0.56 mg of Picibanil. As judged by physical examination and radiographic studies, 5 children (42%) showed a complete or substantial response, and 2 children (16%) showed an intermediate response. No response was seen in 5 children (42%), 2 of whom had massive craniofacial lymphangioma. Factors that contribute to failure with Picibanil sclerotherapy are the presence of a significant microcystic component to the lesion, massive craniofacial involvement, and previous surgical resection. Macrocystic lymphangiomas of the infratemporal fossa or cervical area have the best response to therapy.
匹奇班尼（OK-432）是一种由低毒力化脓性链球菌菌株衍生而来的硬化剂，可促使大囊型淋巴管瘤消退。本报告描述了一项前瞻性、非随机试验，以评估匹奇班尼治疗13例年龄在1至94个月的患病儿童的疗效。平均每名儿童进行了4.1次在荧光镜引导下的囊内注射，匹奇班尼的平均总剂量为0.56毫克。根据体格检查和影像学研究判断，5名儿童（42%）显示出完全或显著反应，2名儿童（16%）显示出中度反应。5名儿童（42%）无反应，其中2名患有巨大的颅面淋巴管瘤。导致匹奇班尼硬化治疗失败的因素包括病变中存在显著的微囊成分、广泛的颅面受累以及既往手术切除。颞下窝或颈部的大囊型淋巴管瘤对治疗反应最佳。
